Soner ÇANKAYA, Sevda ÖNDER, Tülin BAYRAK, Murat ÖZTÜRK, Yasemin KAYA

Evaluation of cardiometabolic function with serum adropin levels in psoriasis patients

Aim: Psoriasis is a skin disease with metabolic and cardiac comorbidities. Adropin is a peptide hormone which is thought to play arole in metabolic diseases, energy homeostasis, endothelial function and cardiac diseases in recent years. In this study, we aimed toevaluate adropin levels in psoriasis patientsMaterials and Methods: The study included 51 plaque psoriasis patients aged 18-65 years who had no systemic disease and hadnot received systemic treatment in the last three months and 37 healthy controls matched by sex, age and body mass index (BMI).Serum adropin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), andtriglyceride (TG), fasting blood glucose (FBG), fasting serum insulin, BMI, systolic blood pressure (SBP) and diastolic blood pressure(DBP) values were recorded.Results: Serum adropin level was 73.04 ± 46.21 pg / ml in the patient group. In the control group, serum adropin level was 77.26 ±43.69 pg / ml. Serum adropin levels were lower in the patient group, but this was not statistically significant (p = 0.667). PASI valuewas negatively correlated with serum adropin level. There was no correlation between serum adropin level and other variables.Insulin level, Homa-IR level, systolic and diastolic pressure were significantly higher in the patient group (p

PDF

___

1. Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol 2014;32:343-50.
2. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017;140:645-53.
3. Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci 2017;19:58.
4. Baran A, Myśliwiec H, Kiluk P, et al. Serum irisin levels in patients with psoriasis. J Dermatolog Treat 2017;28:304-8.
5. Baran A, Myśliwiec H, Szterling-Jaworowska M, et al. Serum YKL-40 as a potential biomarker of inflammation in psoriasis. J Dermatolog Treat. 2018;29:19-23.
6. Baran A, Świderska M, Myśliwiec H, et al. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels. J Dermatolog Treat 2017;28:136- 40.
7. Lovren F, Pan Yi, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122:185-92
8. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468-81.
9. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 2013;380: 73-81.
10. Yildirim B, Celik O, Aydin S. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol 2014;41:310-2.
11. Sayain O, Tokgoz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 2014;27:479-84.
12. Zhang S, Chen Q, Lin X, et al. A Review of Adropin as the Medium of Dialogue between Energy Regulation and Immune Regulation. Oxid Med Cell Longev 2020.
13. Gao Su, McMillan RP, Jacas J, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes 2014;63:3242-52.
14. Kume T, Calan M, Yilmaz O, et al. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest 2016; 39: 747-54.
15. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med 2013;41:375-80.
16. Sen H, Erbag G, Bınnetoglu E, et al. Adropin Levels in Polycystic Ovary Syndrome Patients. J Clin Anal Med 2017;8:23-6.
17. Ko SH, Chi CC, Yeh ML, et al. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev 2019;16:CD011972.
18. Korkmaz S, Sayilan Ozgun G. Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters. Turk J Med Sci 2019;11:110-5.
19. Pektas SD, Pektas G, Oztekin A, et al. Investigation of adropin and IMA levels in psoriasis and their relation to duration and severity of disease. Our Dermatol Online 2018;9:363-8
20. Ganesh Kumar K, Zhang J, Gao Su. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012;20:1394–402
21. Akcilar R, Kocak FE, Simsek H, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocininduced type 2 diabetic rats. Bratisl Lek Listy 2016;117:100-5.
22. Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 2014;52:751-8.
23. Beigi A, Shirzad N, Nikpour F, et al. Association between serum adropin levels and gestational diabetes mellitus; a case-control study. Gynecol Endocrinol 2015;31:939-41.
24. Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptide. 2013;47:66-70.
25. Zang H, Jiang F, Cheng X, et al. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J 2018;28:685-91.
26. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 2012;97:3783-91.
27. Lian W, Gu X, Qin Y, et al. Elevated plasma levels of adropin in heart failure patients. Intern Med 2011;50:1523-7.
28. Altincik A, Sayin O. Evaluation of the relationship between serum adropin levels and blood pressure in obese children. J Pediatr Endocrinol Metab 2015;28: 1095-100.
29. Yu Hy, Zhao P, Wu Mc, et al. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept 2014;190-191:46-9.
30. Topuz M, Celik A, Aslantas T, et al. Plasma adropin levels predict endothelial dysfunction like flowmediated dilatation in patients with type 2 diabetes mellitus. J Investig Med 2013;61:1161-4.
31. Zhang C, Zhao L, Xu W, Li J, Wang B, Gu X, Chen J. Correlation of serumadropin level with coronary artery disease. Zhonghua Yi Xue Za Zhi 2014;94:1255-7.
32. Chen M, Ouyang F, Zhou S. Adropin as a novel energy factor likely has the ability to regulate blood pressure. Med Hypotheses 2015;85:234.
33. Gu X, Li H, Zhu X, et al. Inverse Correlation Between Plasma Adropin and ET-1 Levels in Essential Hypertension: A Cross-Sectional Study. Medicine (Baltimore) 2015;94:e1712.
34. Gulen B, Eken C, Kucukdagli OT, et al. Adropin levels and target organ damage secondary to high blood pressure in the ED. Am J Emerg Med 2016;34:2061-4.